Compass Therapeutics to Participate in the SVB Securities Global Biopharma Conference
02 févr. 2023 08h30 HE
|
Compass Therapeutics
BOSTON, Feb. 02, 2023 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics...
Compass Therapeutics Announces that the Phase 2 Data of CTX-009 in Combination with Paclitaxel in Patients with Biliary Tract Cancers (BTC) will be Presented at the ASCO GI Cancers Symposium on January 20, 2023
19 janv. 2023 17h00 HE
|
Compass Therapeutics
Compass to Host Investor Event on Monday, January 23rd at 8:30am ET CTX-009 in combination with paclitaxel demonstrated a 37.5% overall response rate (ORR) in 24 patients with BTC treated in the...
Dyadic's DYAI-100 COVID-19 Vaccine Study Published in a Leading Peer-Reviewed Scientific Journal
14 déc. 2022 08h30 HE
|
Dyadic International, Inc.
“Thermophilic Filamentous Fungus C1-Cell-Cloned SARS-CoV-2-Spike-RBD-Subunit-Vaccine Adjuvanted with Aldydrogel®85 Protects K18-hACE2 Mice against Lethal Virus Challenge” Study supports: Dyadic’s...
The Top 6 Global Manufacturer and manufacturing capabilities in Antibody market 2023 | forecast to a readjusted size of USD 13230 million by 2028 with a CAGR of 5.1%
16 nov. 2022 02h06 HE
|
Proficient Market Insights
Pune, Nov. 16, 2022 (GLOBE NEWSWIRE) -- "Antibody Market" research report focus on overall information that can help to take decisions on current market situation. The Antibody market report...
Compass Therapeutics to Present at Upcoming Investment Conferences
08 nov. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
Compass Therapeutics Announces $80 Million Private Placement
02 nov. 2022 09h06 HE
|
Compass Therapeutics
BOSTON, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), (“Compass”), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to...
SERB presents preclinical data showing initial efficacy of COVID-19 treatment developed with polyclonal antibody platform
19 oct. 2022 08h24 HE
|
SERB Pharmaceuticals
Washington D.C., Oct. 19, 2022 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals today announces preclinical data demonstrating initial efficacy of a new polyclonal, ovine fragment antibody (Fab) developed...
Compass Therapeutics Announces Clinical Collaboration with Merck to Evaluate CTX-471 in Combination with KEYTRUDA® (pembrolizumab)
11 oct. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...
$18+ Bn Monoclonal Antibody Diagnostic Reagent Market - 13.5% CAGR by 2028, Globally - Rising Prevalence of Cancer and Chronic Diseases, Extensive R&D Efforts to Develop Novel Therapies, Presence of Strong Pipeline of Drugs Under Trial
03 oct. 2022 06h55 HE
|
The Insight Partners
New York, Oct. 03, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on "Monoclonal Antibody Diagnostic Reagent Market Size, Share, Revenue, Growth Strategy, Industry...
Compass Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference
09 sept. 2022 08h00 HE
|
Compass Therapeutics
BOSTON, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer,...